Answers are grounded in this paper and cite their sources.
This study aimed to evaluate the efficacy and safety of particle therapy (PT) for kidney cancer by analyzing data from a multicenter registry study and comparing outcomes with those of stereotactic body radiation therapy (SBRT) through a systematic review and meta-analysis. Patients with kidney cancer who received PT between May 1, 2016 and October 31, 2022, were identified from the Proton Net for proton beam therapy (PBT) and J-CROS for carbon-ion radiotherapy (CIRT). The assessed outcomes included overall survival (OS), progression-free survival (PFS), local control (LC), incidence of grade ≥ 3 late adverse events (AEs) and changes in the estimated glomerular filtration rate (eGFR) at 3 years after PT. Fifty-nine patients (median age 71 years) were analyzed, including 15 (25%) with tumors >40 mm in diameter. The median follow-up was 44.3 months. The 3-year OS, PFS and LC were 92.0%, 82.7% and 94.6%, respectively. The 3-year incidence of treatment-related grade ≥ 3 late AE was 0%. The median change in eGFR at 3 years was −12.0 mL/min/1.73 m2 (range, −38.2 to +5.9). The systematic review identified 14 eligible studies. In the meta-analysis, the 3-year OS was significantly higher in the PT group than in the SBRT group (92.4% vs 79.2%, P = 0.0175) in an unadjusted indirect comparison, while no significant differences were found for other outcomes. A critical risk of bias due to confounding details and the limited number of patients preclude definitive comparative conclusions; and future prospective studies are warranted, particularly for large tumors for which SBRT becomes challenging.
No takes yet. Share an insight, caveat, or question.
Nishioka et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: